A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction (VICTOR)

  • End date
    Jun 15, 2025
  • participants needed
  • sponsor
    Merck Sharp & Dohme LLC
Updated on 29 October 2022


The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.

Condition Chronic Heart Failure With Reduced Ejection Fraction
Treatment Placebo, Vericiguat
Clinical Study IdentifierNCT05093933
SponsorMerck Sharp & Dohme LLC
Last Modified on29 October 2022


Yes No Not Sure

Inclusion Criteria

History of chronic HF [New York Heart Association (NYHA) Class II to IV] on guideline-directed medical therapy for heart failure (GDMT) with no HF hospitalization within 6 months or outpatient IV diuretic use within 3 months before randomization
Left ventricular ejection fraction (LVEF) of ≤40%, assessed within 12 months before randomization by any imaging method
A female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP), or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention
Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels

Exclusion Criteria

Awaiting heart transplantation, is receiving continuous IV infusion of an inotrope, or has or anticipates receiving an implanted ventricular assist device
Has SBP <100 mm Hg or symptomatic hypotension
Amyloidosis or sarcoidosis
Hypertrophic cardiomyopathy
Primary valvular heart disease requiring surgical procedure or intervention or has undergone a valvular surgical procedure or intervention within 3 months before randomization
Acute myocarditis or Takotsubo cardiomyopathy
History of heart transplant
Tachycardia-induced cardiomyopathy and/or uncontrolled tachyarrhythmia
Acute coronary syndrome, or undergone coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within 3 months before randomization
History of symptomatic carotid stenosis, transient ischemic attack (TIA), or stroke within 3 months before randomization
Malignancy or other noncardiac condition limiting life expectancy to <3 years
Requires continuous home oxygen for severe pulmonary disease
Interstitial lung disease
Discontinuation or dose modification of GDMT or vericiguat within 4 weeks before randomization
Recent history (within the last year) of drug or alcohol abuse or dependence
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note